Compare Quantumscape Corp (QS) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quantumscape Corp vs Smith & Nephew plc — how do they compare? Quantumscape Corp trades at $4.66 (market cap $2.78B), while Smith & Nephew plc trades at $27.21 (market cap $11.31B). The key difference: Smith & Nephew plc is far larger — about 4.1× Quantumscape Corp's market cap, and Smith & Nephew plc pays a 2.95% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quantumscape Corp for 37 Days and Smith & Nephew plc for 120 Days on average.
| QS | SNN | |
|---|---|---|
Market Cap | $2.78B | $11.31B |
Volume | 11,236,221 | 1,050,005 |
Sector | Consumer Cyclical | Health |
52-Week High | $18.44 | $37.17 |
52-Week Low | $4.52 | $26.42 |
Typical Hold Time | 37 Days | 120 Days |
Enterprise Value | $1.99B | $14.35B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QuantumScape (QS) trades at $4.52, down 2.8% today, reflecting ongoing investor skepticism about the solid-state battery developer's commercial timeline. The company remains pre-revenue with negative $435M net income in 2025, though it has beaten EPS estimates in two of the last three quarters. Technical indicators show bearish momentum with the stock trading near key support levels, while analyst sentiment remains cautious with 73% hold ratings.
QS faces significant execution risk with commercialization not expected until 2029, creating substantial uncertainty for investors. The stock trades at a discount to the $10.35 consensus target, offering potential upside if technology milestones are met, but requires high risk tolerance given the lengthy path to profitability and intense competition in battery technology.
SNN trades at $26.96, near its 52-week low, with a bearish technical signal. The company has shown improving fundamentals, with revenue growing from $5.2B in 2022 to $6.16B in 2025 and net income margin expanding to 10.08%. Recent product launches, like the EVOS PELVIC System, highlight innovation, but the stock faces negative sentiment from analyst downgrades and CFO departure news.
The outlook is mixed: strong profitability and cash flow support value, but bearish technicals and cautious analyst consensus (26% buy, 65% hold) suggest limited near-term upside. Key risks include execution challenges and competitive pressures. Investors should weigh solid fundamentals against weak market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
